{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:03Z","timestamp":1787009043660,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Global Medical Grant","award":["70145405"],"award-info":[{"award-number":["70145405"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the stability of ceftazidime\/avibactam in elastomeric infusers, utilizing the UK\u2019s Yellow Cover Document (YCD) stability testing framework, in conditions representative of OPAT practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ceftazidime\/avibactam was reconstituted with sodium chloride 0.9% (w\/v) in two elastomeric infusers at concentrations (dose) levels of 1500\/375, 3000\/750 and 6000\u2005mg\/1500\u2005mg in 240\u2005mL. The infusers were exposed to a fridge storage (2\u00b0C\u20138\u00b0C) for 14\u2005days followed by 24\u2005h in-use temperature (32\u00b0C).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 14\u2005days of fridge storage and subsequent 24\u2005h exposure to 32\u00b0C, mean\u200a\u00b1\u200aSD of ceftazidime percent remaining was 75.5%\u200a\u00b1\u200a1.8%, 79.9%\u200a\u00b1\u200a1.1%, 82.4%\u200a\u00b1\u200a0.6%, for Easypump, and 81.7%\u200a\u00b1\u200a1.2%, 82.5%\u200a\u00b1\u200a0.5%, 85.4%\u200a\u00b1\u200a1.1% for Dosi-Fuser devices at the high, intermediate and low doses tested, respectively. For avibactam, mean\u200a\u00b1\u200aSD percent remaining was 83.2%\u200a\u00b1\u200a1.8%, 87.4%\u200a\u00b1\u200a2.0%, 93.1%\u200a\u00b1\u200a0.9% for Easypump, and 85.1%\u200a\u00b1\u200a2.0%, 86.7%\u200a\u00b1\u200a0.1%, 92.5%\u200a\u00b1\u200a0.1% for Dosi-Fuser devices. The cumulative amount of pyridine generated in the devices ranged from 10.4\u2005mg at low dose to 76.9\u2005mg at high dose. Regression-based simulation showed that the degradation of both ceftazidime and avibactam was &amp;lt;10% for at least 12\u2005h of the running phase, if stored in a fridge for not more than 72\u2005h prior to in-use temperature exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Whilst not meeting the strict UK YCD criteria for \u22645% degradation, ceftazidime\/avibactam may be acceptable to administer as a continuous 12\u2005hourly infusion in those territories where degradation of \u226410% is deemed acceptable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae056","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T19:07:59Z","timestamp":1710875279000},"source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of the stability of ceftazidime\/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework"],"prefix":"10.1093","volume":"6","author":[{"given":"Saiyuri","family":"Naicker","sequence":"first","affiliation":[{"name":"The University of Queensland Centre for Clinical Research , University of Queensland, Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research , University of Queensland, Brisbane , Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane , Australia"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier , N\u00eemes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Won","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research , University of Queensland, Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-9854","authenticated-orcid":false,"given":"Steven C","family":"Wallis","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research , University of Queensland, Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Unwin","sequence":"additional","affiliation":[{"name":"Infection Management Services, Princess Alexandra Hospital, Metro South Health , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Jamieson","sequence":"additional","affiliation":[{"name":"Medical Directorate, NHS England (Midlands) , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hills","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Nottingham University Hospitals NHS Trust , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\/Infection, Imperial College Healthcare NHS Trust , London , UK"},{"name":"Department of Infectious Diseases, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-245X","authenticated-orcid":false,"given":"Mark","family":"Santillo","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospitals Plymouth NHS Trust , Plymouth , UK"},{"name":"Pharmacy Department, University Hospitals Bristol and Weston NHS Trust , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-0597","authenticated-orcid":false,"given":"R Andrew","family":"Seaton","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Drummond","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade B","family":"Sime","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research , University of Queensland, Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2024042912100843100_dlae056-B1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"2024042912100843100_dlae056-B2","first-page":"479","article-title":"Ceftazidime-avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections","volume":"41","author":"Mosley","year":"2016","journal-title":"P T"},{"key":"2024042912100843100_dlae056-B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgar.2021.04.015","article-title":"Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime\/avibactam: a retrospective cohort study","volume":"26","author":"Goncette","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2024042912100843100_dlae056-B4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.eimc.2016.08.002","article-title":"First case of ceftazidime\/avibactam administration in home care. ESBL producing Klebsiella pneumoniae bacteremia","volume":"35","author":"Torres-Del-Pliego","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2024042912100843100_dlae056-B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ejhpharm-2019-001875","article-title":"Systematic review of stability data pertaining to selected antibiotics used for extended infusions in outpatient parenteral antimicrobial therapy (OPAT) at standard room temperature and in warmer climates","volume":"27","author":"Perks","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2024042912100843100_dlae056-B6","author":"NHS"},{"key":"2024042912100843100_dlae056-B7","author":"Jamieson"},{"key":"2024042912100843100_dlae056-B8","author":"USP"},{"key":"2024042912100843100_dlae056-B9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/AAC.45.9.2643-2647.2001","article-title":"Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients","volume":"45","author":"Servais","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024042912100843100_dlae056-B10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ajhp\/55.7.683","article-title":"Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device","volume":"55","author":"Stendal","year":"1998","journal-title":"Am J Health Syst Ph"},{"key":"2024042912100843100_dlae056-B11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/antibiotics11040458","article-title":"Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024042912100843100_dlae056-B12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ajhp\/zxy035","article-title":"Ceftazidime stability and pyridine toxicity during continuous i.v. infusion","volume":"76","author":"Jones","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2024042912100843100_dlae056-B13","first-page":"275","article-title":"The mechanism of ceftazidime degradation in aqueous solutions","volume":"55","author":"Zajac","year":"1998","journal-title":"Acta Pol Pharm"},{"key":"2024042912100843100_dlae056-B14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archinte.1943.00210010101008","article-title":"Toxicity of pyridine in man","volume":"71","author":"Pollock","year":"1943","journal-title":"Arch Intern Med"},{"key":"2024042912100843100_dlae056-B15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0147-6513(83)90071-4","article-title":"Ecotoxicological profile of pyridine","volume":"7","author":"Jori","year":"1983","journal-title":"Ecotox Environ Safe"},{"key":"2024042912100843100_dlae056-B16","author":"SCOEL"},{"key":"2024042912100843100_dlae056-B17","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02637-13","article-title":"How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?","volume":"58","author":"Bourget","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024042912100843100_dlae056-B18","first-page":"119P","article-title":"Species variations in the N-methylation and quaternization of [14C]-pyridine in vivo [proceedings]","volume":"68","author":"Caldwell","year":"1980","journal-title":"Brit J Pharmacol"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/2\/dlae056\/57341999\/dlae056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/2\/dlae056\/57341999\/dlae056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:16:11Z","timestamp":1714378571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae056\/7641086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae056","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,5]]},"article-number":"dlae056"}}